| Zacks Company Profile for Lineage Cell Therapeutics, Inc. (LCTX : AMEX) |
|
|
| |
| • Company Description |
| Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.
Number of Employees: 77 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.03 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,933,144 shares |
| Shares Outstanding: 228.36 (millions) |
| Market Capitalization: $235.21 (millions) |
| Beta: 1.60 |
| 52 Week High: $1.15 |
| 52 Week Low: $0.37 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
27.08% |
21.34% |
| 12 Week |
151.22% |
112.01% |
| Year To Date |
104.97% |
92.59% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
2173 SALK AVENUE SUITE 200
-
CARLSBAD,CA 92008
USA |
ph: 442-287-8990
fax: 510-521-3389 |
ir@lineagecell.com |
https://lineagecell.com |
|
|
| |
| • General Corporate Information |
Officers
Brian M. Culley - Chief Executive Officer and Director
Jill Ann Howe - Chief Financial Officer
Deborah Andrews - Director
Dipti Amin - Director
Don M. Bailey - Director
|
|
Peer Information
Lineage Cell Therapeutics, Inc. (CORR.)
Lineage Cell Therapeutics, Inc. (RSPI)
Lineage Cell Therapeutics, Inc. (CGXP)
Lineage Cell Therapeutics, Inc. (BGEN)
Lineage Cell Therapeutics, Inc. (GTBP)
Lineage Cell Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 53566P109
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 228.36
Most Recent Split Date: 10.00 (3.00:1)
Beta: 1.60
Market Capitalization: $235.21 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.02 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.09 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
